Elevation of β-Amyloid 1-42 Autoantibodies in the Blood of Amnestic Patients With Mild Cognitive Impairment (original) (raw)
Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide
Yansheng Du
Biological Psychiatry, 2005
View PDFchevron_right
Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression
Cristiana Barbati
Autoimmunity Reviews, 2010
View PDFchevron_right
Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients
Hayrettin Tumani
PLoS ONE, 2013
View PDFchevron_right
Amyloid-β42 plasma levels are elevated in amnestic mild cognitive impairment
Cristina Novello
Journal of Alzheimer's Disease, 2009
View PDFchevron_right
Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
George Godsey
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2016
View PDFchevron_right
Plasma levels of amyloid -protein 42 are increased in women with mild cognitive impairment
alessandra argusti
2004
View PDFchevron_right
Specific reactivity of mild/severe Alzheimer’s disease patient’s sera to antibody against Aβ1-40 epitope 17-21
Funda Hatip
Acta Neurologica Scandinavica, 2007
View PDFchevron_right
Distinct Patterns of Antiamyloid-β Antibodies in Typical and Atypical Alzheimer Disease
Olivier Colliot
Archives of Neurology, 2012
View PDFchevron_right
Several direct and calculated biomarkers from the amyloid-β pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment
ITZIAR SAN JOSÉ
View PDFchevron_right
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
Eliana Alonso
Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018
View PDFchevron_right
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals
Paul Szabo, Marc Weksler
Experimental Gerontology, 2002
View PDFchevron_right
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Dwight German
Journal of Neuroimmunology, 2014
View PDFchevron_right
Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes
Bart Van Berckel
Annals of neurology, 2018
View PDFchevron_right
Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition
Nikhil Thaker
Journal of Alzheimer's disease : JAD, 2011
View PDFchevron_right
Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
ITZIAR SAN JOSÉ
View PDFchevron_right
Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline
Deborah Blacker
Archives of Neurology, 2012
View PDFchevron_right
Antigenantibody dissociation in Alzheimer disease: a novel approach to diagnosis
R. Friedland, Xiongwei Zhu, Robert B Petersen, George Perry
Journal of Neurochemistry, 2008
View PDFchevron_right
Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
Elisabet Londos
Neurobiology of Aging, 2010
View PDFchevron_right
Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias
Patrizia Mecocci
Brain, Behavior, and Immunity, 1992
View PDFchevron_right
Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers
George Godsey
Journal of Alzheimer's Disease
View PDFchevron_right
Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
Akira Tamaoka
Journal of the Neurological Sciences, 1997
View PDFchevron_right
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Vitaliy Ovod
JAMA Neurology
View PDFchevron_right
Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?
Philip Scheltens
Annals of Neurology, 2005
View PDFchevron_right
Immune complexes of auto-antibodies against Aβ1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients
Andreas Henkel
Molecular Psychiatry, 2007
View PDFchevron_right
Plasma A 40 and A 42 and Alzheimer's disease: Relation to age, mortality, and risk
Richard Mayeux
Neurology, 2003
View PDFchevron_right
Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer’s disease: A population-based study
Kasia Gustaw Rothenberg
Experimental Gerontology, 2010
View PDFchevron_right
Differences and Similarities between Two Frequently Used Assays for Amyloid 42 in Cerebrospinal Fluid
hugo vanderstichele
Clinical Chemistry, 2005
View PDFchevron_right
Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study
Jacques Touchon
Journal of Alzheimer's disease : JAD, 2013
View PDFchevron_right